SCHEMBL4981689

SCHEMBL4981689

CCCCCCCCCC(O)CC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 8/20 0.50
FFAR1 O14842 2/20 0.48
FFAR4 Q5NUL3 1/20 0.48
SPHK1 Q9NYA1 2/20 0.43
PSMD14 O00487 2/20 0.43
PLA2G1B P04054 2/20 0.43
MMP2 P08253 2/20 0.43
ATG4B Q9Y4P1 2/20 0.43
LMNA P02545 2/20 0.43
HSP90AA1 P07900 1/20 0.43
RAD52 P43351 1/20 0.43
NFKB1 P19838 1/20 0.42
CYP2D6 P10635 2/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25696415 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL14273257 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL27069770 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL8240576 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL8240389 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL8240228 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL8234190 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL8240466 1.00 GPR84 (0.50) GPR84FFAR1FFAR4SPHK1PSMD14
SCHEMBL12595644 0.91 GPR84 (0.39) GPR84FFAR1FFAR4NFKB1
SCHEMBL16074962 0.84 GPR84 (0.48) GPR84FFAR1FFAR4SPHK1PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008045555-A9 FUEL COMPOSITIONS COMPRISING FARNESANE AND FARNESANE DERIVATIVES AND METHOD OF MAKING AND USING SAME AMYRIS BIOTECHNOLOGIES INC (US) 2008-10-23 WO disclosed
US-7335725-B2 Lipopeptides as antibacterial agents CUBIST PHARMACEUTICALS, INC. (US) 2008-02-26 US disclosed
US-20050203006-A1 Novel lipopeptides as antibacterial agents MERCK SHARP & DOHME CORP. 2005-09-15 US disclosed
EP-0531715-B1 Process for producing alcohols and ketones SUMITOMO CHEMICAL CO (JP) 1997-11-05 EP disclosed
US-5426237-A Oxidation of straight, branched or cyclic alkanes and benzene derivatives in presence of transition metal catalyst and aldehyde SUMITOMO CHEMICAL CO., LTD. (JP) 1995-06-20 US disclosed
EP-0531715-A1 Process for producing alcohols and ketones SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203006-A1 Novel lipopeptides as antibacterial agents CLPTM1, NGLY1, VIP GPR84 2944/4885FFAR1 2172/4885FFAR4 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.